Bio-Techne Corporation
TECH
주식 순위
#1874
Bio-Techne Corporation, together with its subsidiaries, develops, manufactures,... Bio-Techne Corporation, together with its subsidiaries, develops, manufactures, and sells life science reagents, instruments, and services for the research, diagnostics, and bioprocessing markets worldwide. The company operates through two segments, Protein Sciences, and Diagnostics and Spatial Biology. The Protein Sciences segment develops and manufactures biological reagents used in various aspects of life science research, diagnostics, and cell and gene therapy, such as cytokines and growth factors, antibodies, small molecules, tissue culture sera, and cell selection technologies. This segment also offers proteomic analytical tools for automated western blot and multiplexed ELISA workflow consists of manual and automated protein analysis instruments and immunoassays for use in quantifying proteins in various biological fluids. The Diagnostics and Genomics segment develops and manufactures diagnostic products, including controls, calibrators, and diagnostic assays for regulated diagnostics market, exosome-based molecular diagnostic assays, advanced tissue-based in-situ hybridization assays for spatial genomic and tissue biopsy analysis, and genetic and oncology kits for research and clinical applications; and sells products for genetic carrier screening, oncology diagnostics, molecular controls, and research, as well as instruments and process control products for hematology, blood chemistry and gases, and coagulation controls and reagents used in various diagnostic applications. The company was formerly known as Techne Corporation and changed its name to Bio-Techne Corporation in November 2014. Bio-Techne Corporation was incorporated in 1976 and is headquartered in Minneapolis, Minnesota.
주가
$72.55
마지막 동기화: 2026-10-16
시가총액
$11.38B
변동 (1일)
0.03%
변동 (1년)
17.27%
국가
US
거래 Bio-Techne Corporation (TECH)
카테고리
Healthcare
Bio-Techne Corporation (TECH)의 영업이익률
October 2026 기준 영업이익률 TTM: 20.73%
Bio-Techne Corporation의 최신 재무 보고서와 주가에 따르면 현재 영업이익률 (TTM)은 20.73%입니다. 2024년 말 기준 영업이익률은 17.83%였습니다.
Bio-Techne Corporation의 영업이익률 기록 (2000 ~ 2026)
매년 말 영업이익률
| 연도 | 영업이익률 | 변화 |
|---|---|---|
| 2026 (TTM) | 20.73% | 147.37% |
| 2025 | 8.38% | -53.00% |
| 2024 | 17.83% | -32.21% |
| 2023 | 26.30% | -1.98% |
| 2022 | 26.83% | 67.06% |
| 2021 | 16.06% | 58.85% |
| 2020 | 10.11% | -42.52% |
| 2019 | 17.59% | -16.95% |
| 2018 | 21.18% | -2.08% |
| 2017 | 21.63% | -28.33% |
| 2016 | 30.18% | -7.17% |
| 2015 | 32.51% | -27.19% |
| 2014 | 44.65% | -12.49% |
| 2013 | 51.02% | -3.44% |
| 2012 | 52.84% | -6.03% |
| 2011 | 56.23% | -3.22% |
| 2010 | 58.10% | 1.72% |
| 2009 | 57.12% | 1.91% |
| 2008 | 56.05% | 0.90% |
| 2007 | 55.55% | 3.73% |
| 2006 | 53.55% | -2.14% |
| 2005 | 54.72% | 7.25% |
| 2004 | 51.02% | 9.25% |
| 2003 | 46.70% | 15.74% |
| 2002 | 40.35% | 1.61% |
| 2001 | 39.71% | 4.80% |
| 2000 | 37.89% | 0.00% |
유사 기업 또는 경쟁사의 영업이익률
| 회사 | 영업이익률 | 영업이익률 차이 | 국가 |
|---|---|---|---|
| 38.59% | -98.14% |
US
|
|
| -149.01% | -107.19% |
US
|
|
| 25.57% | -98.77% |
AU
|
|
| 0.00% | - |
CH
|
|
| 28.81% | -98.61% |
NL
|
회사의 영업이익률이란?
영업이익률은 회사의 수익성을 평가하는 핵심 지표입니다. 높은 영업이익률은 일반적으로 긍정적으로 간주되며, 이는 회사가 제품이나 서비스를 생산 비용보다 훨씬 높은 가격에 판매할 수 있음을 보여줍니다. 영업이익률은 회사의 수익을 매출로 나누어 계산합니다.